Orano Med
Carter Rose is a seasoned professional in production management and research, currently serving as Senior Production Manager and Associate RSO at Orano Med since September 2022, where Carter is instrumental in establishing commercial manufacturing operations. Previous experience includes roles as Production Lead and Technician at Advanced Accelerator Applications, contributing to the production of Lutathera and Pluvicto. Carter's background includes research internships at The University of Vermont Medical Center and Marin Biologic Laboratories, focusing on quality improvement projects and assisting with drug development. Additionally, Carter held the position of President for the UVM Men's Club Lacrosse team, demonstrating leadership skills from earlier experiences in the Boy Scouts of America, where Carter achieved the rank of Eagle Scout. Carter holds a Bachelor's of Arts in Biology with a minor in Chemistry from the University of Vermont.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.